We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Tampilkan postingan dengan label Embryonic. Tampilkan semua postingan
Tampilkan postingan dengan label Embryonic. Tampilkan semua postingan

Sabtu, 08 Oktober 2011

Scientists hail gain in human embryonic stem cell research

AppId is over the quota
AppId is over the quota
The achievement is an "important step" in stem cell research, scientists say They used a technique similar to the one used to clone Dolly the sheepThe motivation for the research was to eventually cure diseases such as Parkinson's, diabetes

(CNN) -- For the first time, researchers have succeeded in creating human embryonic stem cells by injecting DNA from a skin cell into an unfertilized egg, according to a study published Wednesday.

To achieve what is being called an "important step" in stem cell research, scientists in New York used a cloning technique similar to the one used to clone Dolly the sheep.

"This work now demonstrates for the first time that the human egg has the ability to turn a specialized cell into a stem cell," said Dieter Egli, who along with fellow study author Scott Noggle led the research team at the New York Stem Cell Foundation.

"The goal of this research was to create patient-specific embryonic stem cells with the patients' DNA for the eventual use in cell replacement therapy," Egli told CNN.

He said the motivation for the research was to eventually cure diseases such as Parkinson's, diabetes and many other illnesses.

In 2005, researchers in South Korea claimed to have created the first human embryonic stem cells by cloning an embryo. A year later, it was revealed that the data had been faked.

This new study, published in the journal Nature, shows researchers have finally succeeded in creating human embryonic stem cells. They weren't perfect though because they have too many chromosomes -- 69 instead of the usual 46 -- making the cells suitable for research purposes only, not actual treatments.

In the past, efforts to create human stem cells using cloning meant taking an unfertilized egg, removing egg's nucleus with its 23 chromosomes and replacing it with the nucleus of a skin cell (which has 46 chromosomes) and placing the egg in a chemical bath to make it divide as if it had been fertilized by sperm.

Researchers started out with 270 donated oocytes or unfertilized eggs, provided by sixteen egg donors, Noggle said.

Egli said through a process of elimination, he and his colleagues determined that it was the removal of the egg's genome, not the introduction of new DNA or chemically initiating cell division, which was preventing the egg to develop far enough along so stem cells can be extracted. Noggle says 63 eggs were needed to develop two cell lines, of which one was viable.

"It's the machinery within the egg that allows the egg to progress normally in development," said Ted Golos, who is a professor of Comparative Biosciences at the school of Veterinary Medicine at the University of Wisconsin-Madison.

Golos, who is not involved in this new research, says this new study isn't a giant leap forward but it's an interesting one. Now the challenge is to figure out how to remove the egg's chromosomes, without removing the machinery or spindle, which helps the egg divide. Egli said he and his colleagues are working on just that.

Researchers have been using adult stem cells like bone marrow for treatments for decades. But adult stem cells have been programmed for one part of the body and are not easily converted to correcting problems in other parts of the body.

Then the first major advance in human embryonic stem cell research came In 1998, when Jamie Thomson at the University of Wisconsin-Madison, extracted the first stem cells from an existing human embryo.

In 2007, researchers in Japan and California reported the creation of stem cells by bypassing eggs altogether and reprogramming skin cells directly into dividing like fertilized eggs with the addition of four viruses.

These cells are called induced pluripotent stem cells or iPS cells. Since then, researchers have found these cells have some limitations as well. While some opponents of embryonic research believe advances in the "less controversial" adult stem cell and iPS cells eliminate the need for embryonic stem cell research, most experts in the field believe all three research paths need to be explored to eventually find the right treatment for the right disease.

Dr. Alan Trounson, who heads the California Institute for Regenerative Medicine, which funds embryonic and adult stem cell research, says if researchers are able to take the next step and figure out how to make embryonic stem cells without the excess chromosomes, then they can begin to compare them to iPS cells and determine how different or similar they really are.

Egli agrees.

"We need to better understand the biology of the human egg for reprogramming without the egg genome," he said.



Education Information



Technology

Senin, 26 September 2011

Embryonic stem cell test go-ahead

AppId is over the quota
AppId is over the quota
22 September 2011 Last updated at 14:48 GMT By Fergus Walsh Medical correspondent Prof James Bainbridge, from Moorfields Eye Hospital, explains the procedure. Footage courtesy of ACT.

Doctors at Moorfields Eye hospital in London have been given the go-ahead to carry out Europe's first clinical trial using human embryonic stem cells.

They will inject retinal cells into the eyes of 12 patients with an incurable disease, Stargardt's macular dystrophy, which causes progressive sight loss.

The disease develops in childhood and affects around one in 10,000 people.

It causes the gradual loss of central vision leaving only peripheral sight.

The trial will test the safety of using replacement retinal cells known as retinal pigment epithelial cells, derived from human embryonic stem cells.

'Milestone'

The trial is a partnership with an American bio-tech company Advanced Cell Technology (ACT) which has already begun treating patients in California.

Continue reading the main story
There is real potential that people with blinding disorders...might benefit in the future from transplantation of retinal cells”

End Quote Prof James Bainbridge Moorfields Eye Hospital Gary Rabin, chairman and CEO of ACT described the Moorfields trial as "another milestone for the field of regenerative medicine".

Stem cells are the body's master cells - those from human embryos have the potential to turn into any of the 200 or so tissue types in the body.

The stem cell line was created in the United States several years ago using a donated embryo of just a few cells, smaller than a pinhead.

Supporters say embryonic stem cell therapy has the potential to treat not only blindness but a huge range of disorders, from heart disease to cancer.

Opponents object to the procedure because it began with the destruction of a human embryo.

Another US company, Geron, has also used embryonic stem cells to treat patients with spinal injuries.

The Moorfields trial and those in the US involving ACT and Geron are all to test whether the procedure is safe.

If it is, then progressively larger numbers of stem cells will be used to check for effectiveness.

Prof James Bainbridge from Moorfields Eye Hospital said: "There is real potential that people with blinding disorders of the retina including Stargardt's disease and age-related macular degeneration might benefit in the future from transplantation of retinal cells."

Prof Chris Mason, Chair of Regenerative Medicine Bioprocessing, Advanced Centre for Biochemical Engineering, University College London, said: "Whilst principally a safety study, it will undoubted significantly add to the growing core of knowledge on cell therapies, thus helping advance the entire field."

Earlier this year the National Institute of Health Research (NIHR) awarded Moorfields and UCL Institute of Ophthalmology £26m for work aimed at the translation of scientific advances into new treatments for people with sight-threatening disease.



View the original article here



Peliculas Online

Jumat, 23 September 2011

First European Embryonic Stem Cell Trial Gets Green Light

AppId is over the quota
AppId is over the quota

Health authorities in the U.K. approved on Thursday Europe's first clinical trial involving embryonic stem cells.

Surgeons at Moorfields Eye Hospital in London will treat 12 patients with Stargardt's macular dystrophy, a major cause of blindness in young people. Patients with Stargardt's gradually lose retinal pigment epithelial cells, or RPE cells, which are essential for maintaining the proper environment that encourages retinal cells to grow.

Patients in the U.K. trial will receive RPE cells grown from human embryonic stem cells. This is the second human trial to use such cells; the first was approved by the U.S. Food and Drug Administration (FDA) last November, which we described here. In both studies, the cells will be made by Massachusetts-based Advanced Cell Technology (ACT).

The purpose of the trial is to establish the safety of the treatment, so the dozen enrolled patients are at the most advanced stages of the incurable disease. They will receive anywhere from 50,000 to 200,000 cells, injected directly into the eye, behind the retina. Doctors expect that the transplanted cells will then start to grow in their new environment, replacing the diseased and dying ones that have robbed the patients of their vision.

The eye is a good site for testing such a treatment, since it is relatively protected from the immune system; the new cells may therefore be protected from destruction by overzealous defensive cells. The isolated nature of the eye's vitreous cavity, where the cells are injected, also makes it relatively easy for doctors to destroy the transplanted RPE cells should something go wrong, such as if the cells should start forming tumors or migrate to other areas.

The eye trials follow the first ever approved human trial of an embryonic stem cell based-therapy, approved in January 2009 in the U.S. to treat spinal cord injury. The FDA put that trial on hold after some animals receiving the stem cells developed cysts, but the company conducting the trial, Geron, provided additional safety data and new tests for detecting the unusual growths. Last summer the trial was once again allowed to move forward.

Embryonic stem cells could become an important source of replacement cells for a number of different diseases, including diabetes and Parkinson's. As Dr. James Barinbridge, a retinal surgeon at Moorfields and the UCL Institute of Ophthalmology, told the U.K.'s Guardian, "The ability to regenerate retinal cells from stem cells in the laboratory has been a significant advance and the opportunity to help translate such technology into new treatments for patients is hugely exciting. Testing the safety of retinal cell transplantation in this clinical trial will be an important step towards achieving this aim."

Alice Park is a writer at TIME. Find her on Twitter at @aliceparkny. You can also continue the discussion on TIME's Facebook page and on Twitter at @TIME.



View the original article here



Peliculas Online